Targeting the human RED-SMU1 splicing complex as a basis for host-directed anti-influenza therapy

Tue19  Oct02:00pm(30 mins)
Room 3A


Transcription and replication of the influenza A virus (IAV) RNA genome occurs in the nucleus of infected cells. We showed that the RED-SMU1 splicing complex regulates the splicing of the viral NS1 mRNA into the NS2 mRNA encoding the essential NS2/NEP protein. In cells depleted for RED or SMU1, the production of infectious IAVs is reduced by 2-logs, therefore designating the RED-SMU1 complex as a promising drug target.
In a large collaborative effort, we solved the crystal structure of a minimal REDmid-SMU1Nter complex. A short alpha-helix of RED (RED211-221) lies into a hydrophobic groove at the surface of SMU1Nter. We undertook two complementary approaches to target the SMU1Nter-RED221-221 interface. Firstly, we screened in silico a set of small compounds for binding to the groove at the surface of SMU1Nter. We thereby identified compounds that disrupt the RED-SMU1 complex and specifically inhibit IAV replication whilst preserving cell viability. These compounds are now undergoing chemical optimization. Secondly, we used phage display to select RED206-221 variant peptides from large random libraries; these show high affinity for SMU1Nter and are being tested for inhibition of IAV replication. Our investigations pave the way for the development of future host-directed anti-influenza drugs with broad activity against IAV strains and with a low likelihood of resistance mutants.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021